Legal Assault on Medicare Drug Price Law Simmers in Courts (2)

The pharmaceutical industry’s multipronged legal fight against Medicare’s drug price negotiation program is likely to gain steam as manufacturers selected for the first round have just one month to sign agreements entering price talks and to submit manufacturer data to the federal government.

The Centers for Medicare & Medicaid Services on Aug. 29 released the long-awaited list of the first 10 drugs that will have lower, government-negotiated prices starting in 2026. Manufacturers of some of these selected drugs—including Merck & Co., Bristol-Myers Squibb Co., and Johnson & Johnson—are challenging the negotiation program in court. Novartis AG on ...